| CML | Chronic Myeloid Leukemia |
| ALL | Acute Lymphoblastic Leukemia |
| TKI | Tyrosine Kinase Inhibitors |
| Bcr−Abl1 | Breakpoint Cluster Region Protein−Abelson Tyrosine−Protein Kinase 1 |
| EPIC | Evaluation of Ponatinib Versus Imatinib in Chronic Myeloid Leukemia |
| PACE | PIVOTAL Phase−II Ponatinib Ph+ ALL and CML Evaluation |
| ENESTn | Randomized Evaluating Nilotinib Efficacy and Safety in Clinical Trials Newly Diagnosed Patients |
| PT | Prothrombin Time |
| aPTT | Activated Partial Thromboplastin Time |
| TGT | Thrombin Generation Times |
| ROS | Reactive Oxygen Species |
| CRP | Collagen−Related Peptide |
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.